Pfizer Oncology Research & Development (ORD) La Jolla, California, is seeking a Senior Scientist (PhD) focused on translating basic discoveries in the field of cancer epigenetics into novel therapeutics.
The Senior Scientist will lead translational development efforts supporting drug programs currently in clinical development and/or advanced pre-clinical drug discovery stages. Our ideal candidate will have strong translational research experience with hands-on expertise in conducting drug mechanism of action studies, elucidation of drug resistance mechanisms and development of rational drug combination strategies. The candidate will lead biological translational studies utilizing genetic and pharmacological approaches to understand MOA and generate patient stratification strategies for novel cancer therapeutics. As a member of the group, the candidate will work together with a team of motivated and scientifically rigorous scientists to perform laboratory-based research in a collaborative team environment, interpret and present findings at team/project meetings and function as an integral member of the epigenetics team to advance drug programs. The successful candidate will have experience in the integration of molecular profiling data including epigenomic (ATAC-seq, ChIP-seq), transcriptomic, proteomic, and genomic datasets, into a broader understanding of epigenetic regulation in the tumor microenvironment.
- Design, execute and analyze/interpret experiments to advance mechanism of action studies, develop patient responder hypotheses, elucidate mechanisms of resistance and identify rational drug combinations that can be translated to the clinic
- Utilize expertise in epigenetic biology to develop innovative strategies for understanding role epigenetic mechanisms in cancer progression, drug resistance and immune modulation
- Develop and apply complex in vitro assays including organoids for conducting synthetic-lethal, drug combination screens to identify rational combinations and patient selection biomarkers
- Work collaboratively with computational biology group to integrate complex data sets including epigenomic and other ‘omic’ data in pre-clinical settings for target validation and advance mechanism of action target biology
- Collaborate with in vivo pharmacology group for efficacy testing, PK/PD and experimental design of preclinical PoC experiments and develop cell assays to measure pharmacodynamic changes, kinetics of drug response and evaluation of predictive biomarkers
- Interface with discovery biology, systems biology and computational biology groups to design, develop, and interpret datasets developed from genetic and pharmacological screens
- Proactively seek out new information in the literature and incorporate this into individual project(s) as well as the overall program
- Present research results and methodologies at weekly meetings with immediate supervisor and/or project leader, project team meetings and other research forums
- Contribute to building a culture that embraces scientific excellence, urgency, partnerships with key stakeholders, continuous learning and improvement, increasing technical skill base and cancer biology expertise; take a proactive role in personal growth and scientific development.
- PhD in Molecular or Cellular Biology, Genetics, Pharmacology (or a comparable biological science) with a minimum of 3-5 years of relevant postdoctoral experience in an academic or pharmaceutical/biotech environment.
- Expertise in chromatin biology, epigenetics and mechanism of transcriptional regulation as evidenced by publication in peer-reviewed journals.
- Extensive knowledge and experience in areas of tumor biology including, but not limited to immuno-oncology, oncogenic signaling, cancer metabolism, apoptosis and/or DNA damage and repair
- Demonstrate proficiency in the use of software tools to support epigenomic data analysis including ATAC-seq, ChIP-seq, and RNA-seq.
- Experience in use of CRISPR-based techniques for gene knockout, gene editing and as well as working knowledge of pooled CRISPR -based screening approaches
- Able to work in a team environment, good communication skills and excellent leaderships skills.
- Preference for candidates with a strong track record in cancer drug discovery/translational research and the targeting of epigenetic pathways by small-molecule inhibitors.